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Abstract: 
Background. This study assessed counseling and testing needs from the perspective of adult 
members of a large African-American kindred with a BRCA1 mutation. 
Methods. Interviews were conducted with 95 male and female kindred members to elicit 
information on sociodemographics, attitudes toward health care providers, breast cancer 
screening behaviors, and religious/spiritual beliefs, as well as to evaluate psychological distress, 
beliefs, knowledge, and attitudes related to genetic testing. 
Results. Knowledge about breast and ovarian cancer genetics was limited. Adherence to 
screening recommendations was low among females with no personal breast or ovarian cancer 
history. The majority (67%) wished to discuss risk factors with a health care provider. Most 
participants (82%) indicated that they would have a genetic test if it were available. Significant 
predictors of intent to undergo testing were having at least one first-degree relative with breast 
and/ or ovarian cancer (OR = 5.1; 95% CI = 1.2–20.9) and 
perceived risk of being a gene carrier ?50%(OR = 64.3; 
95%CI = 5.1–803.9) or reporting that they did not know their risk of being a gene carrier (OR = 
10.9; 95%CI = 2.1–57.7). Cited barriers to testing included cost and availability. 
Conclusion. There is a high interest level in genetic testing despite limited knowledge about 
cancer genetics among these high-risk African Americans. Our study provides information for 
designing a genetic education and counseling intervention for this and similar families.  
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INTRODUCTION 
Approximately 2–5% of breast cancers and 10% of ovarian cancers can be attributed to 
mutations in the BRCA1 and BRCA2 genes [1,2]. Testing for BRCA1 and BRCA2 is 
commercially available and offers the opportunity to identify patients for whom genetic 
counseling maybe of value. Issues regarding insurability, confidentiality, and potential 
discrimination have been discussed [3,4]; however, little research on the clinical application of 
cancer-related genetic technology for ethnic minority populations has been done [S]. 
Offspring of a female or male BR CA1 carrier are at 50% risk of inheriting the altered gene. 
Female carriers of BRCA1 mutations have an estimated 46–85% lifetime risk of breast cancer 
and a 16–65% risk of ovarian cancer [6f10]. Furthermore, the risk for developing colorectal 
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cancer in male and female BRCA1 mutation carriers and prostate cancer in male carriers may be 
increased [10,11]. 
 
Use of genetic counseling and testing for breast and ovarian cancer susceptibility is increasing in 
clinical settings throughout the United States [12,13]. Because most of the molecular 
epidemiologic research on BRCA1/BRCA2 mutations has focused on Caucasians and those of 
Ashkenazi Jewish origin [7f10], knowledge of the frequency and penetrance of these mutations 
in African Americans is limited. Furthermore, genetic counseling and testing programs 
developed for Caucasian populations may not be culturally sensitive. Thus, it is timely to 
examine factors that will influence genetic counseling and testing programs among individuals 
from diverse cultures and socioeconomic groups. Furthermore, due to the racial disparities in 
incidence and mortality rates for cancer in African Americans, it is critical to target this group 
for screening and prevention interventions. 
 
Prior to developing a genetic counseling and testing protocol for adult members of an extended 
African- American kindred with a BRC,41 mutation, a needs assessment was conducted. This 
needs assessment evaluated adult members of the kindred. Here we describe: (a) their health care 
attitudes and practices; (b) their knowledge about breast and ovarian cancer susceptibility; (c) 
their beliefs and attitudes about breast and ovarian cancer and genetic testing; and (d) breast 
cancer screening behaviors. We also determined predictors of intent to have a genetic test. This 
kindred maybe the first African-American familywith a BR C,41 mutation to be studied in this 
manner. 
 
MATERIALS AND METHODS 
Study Population and Procedures 
Ninety-five adults (all ?18 years of age) were interviewed between July 1998 and February 1999. 
Most live in a small Louisiana town; they are diverse in income, location (rural vs urban), and 
education. The kindred, known as K2099, includes six generations with 36 known cancer cases: 
27 breast, 4 ovarian, 4 colorectal, and 1 prostate. The youngest ages of onset of breast cancer and 
ovarian cancer are 28 and 54 years, respectively. Forty-four percent of the participants partici-
pated in a prior study to isolate BR C,41 [14]. Although the specific mutation in BR C,41 was 
later determined, no further testing has been conducted on the Louisiana members of this 
kindred, and none of the relatives received research results or information about the genetics of 
hereditary breast and ovarian cancer. However, in the course of this psychosocial study, they 
were told that they were at increased risk for developing breast cancer due to family history. 
None of the participants reported having clinical BR C,41 testing prior to participation in the 
present study. 
 
Eligibility criteria for our study included the ability to give written informed consent in English 
and biological kinship to a K2099 member. The study was approved by the University of Utah 
Institutional Review Board. Participants were given the option, when possible, of having 
interviews in person in their homes or in another acceptable location or by telephone. This 
strategy was suggested by family members during the planning phase of the study. Information 
about the study purposes and procedures was sent between July and October 1998. Those not 
interested in the study were requested to return a form indicating that they did not want to be 
contacted further. Those who consented to participate completed a structured in-person (63%) or 
telephone (37%) interview. 
 
Measures 
The in-person or telephone administered questionnaires contained identical measures of 
sociodemographics, clinical variables, psychological distress, religious/spiritual beliefs, and 
attitudes toward genetic counseling and testing. 
 
Background factors. Variables included age, gender, family identification number (to control for 
group-level variance attributable to immediate families), marital status, education, household 
income, history of cancer, and number of first-degree relatives with breast and/ or ovarian 
cancer. 
 
Health care attitudes and utilization. Measures included presence or absence of a regular 
health care provider (HCP) or clinic, interpersonal aspects of health care among female members 
without cancer (unaffected), and utilization of breast cancer screening. The Interpersonal Aspects 
of Care Scale (Communication and Rapport Subscales) of the Adherence Determinants 
Questionnaire assessed and measured interactions with HCPs [15]. Each subscale contains four 
items rated on a 5-point Likert scale from strongly agree to strongly disagree. Internal 
consistency for our sample was acceptable for the total scale (a = 0.77). Cronbach’s a 
coefficients for the Communication and Rapport subscales were 0.67 and 0.62, respectively. 
Participants were asked whether a HCP discussed personal or familial breast cancer risk with 
them and whether they wanted to talk to a care provider about familial cancer. 
 
For unaffected females, breast cancer screening (i.e., mammography, clinical breast exam 
(CBE), and breast self-exam (BSE)) was ascertained by self-report. Adherence for unaffected 
female carriers was determined using guidelines developed for high-risk families by a taskforce 
convened by the Cancer Genetics Study Consortium [11]. These guidelines include the 
following: monthly BSE by age 18 to 21, education and instruction on BSE technique, annual 
CBE by age 25 to 35, and annual mammography beginning between ages 25 and 35 (about 5 
years younger than the earliest age of onset of breast cancer in kindred members). 
 
Psychological distress. The Center for Epidemiologic Studies Depression Scale (CES-D) [16] 
and the Revised Impact of Event Scale [17] were utilized. The 20-item CES-D asks individuals 
to rate the frequency with which they have experienced depressive symptoms, with an emphasis 
on affective components (e.g., hopelessness, sorrow) during the preceding 7 days. Ratings of the 
4-point response scale are summed to yield a score ranging from 0 to 60, with higher scores 
indicating depressive symptoms. The scale has excellent internal consistency in both community 
populations (a = 0.85± 0.87) and our sample (a = 0.92). 
 
The Intrusion Subscale of the Impact of Event Scale was used to measure the frequency and 
severity of intrusive thoughts about having cancer in the family and personal risk of cancer. 
Items are summed with possible scores ranging 0 to 35. Internal consistency was excellent in our 
sample (Cronbach’s a = 0.90). 
 
Knowledge and attitudes about breast cancer and BRCA1. Knowledge was assessed with a 
9-item true± false scale adapted from a core set of instruments developed for the National 
Institutes of Health National Center for Human Genome Research Cancer Genetics Studies 
Consortium [18]. Open-ended questions were used to elicit information on beliefs about the 
causes of breast and ovarian cancer and about perceived major benefits, limitations, and risks of 
genetic susceptibility testing. Perceived risk was assessed by asking participants to rate their 
chances of being an altered breast or ovarian cancer gene carrier on a scale of 0 to 100. 
Participants were also asked to rate the degree to which they agreed or disagreed with 23 Likert-
style items (10 pro and 13 con), which were described as a “list of issues people might consider 
in deciding whether or not to take a genetic test” [19]. 
 
Religiosity/spiritual beliefs. Religious affiliation and a specific type of religiosity, God Locus of 
Health Control (GLHC), were assessed. The 6-item God Locus of Health Control scale assessed 
the belief that God is (or is not) either the locus of control of one’s health status in general or the 
locus of control of one’s specific disease status [20]. Internal consistency was excellent, with a 
coefficients ranging from 0.87 to 0.91 in prior studies and 0.85 in our sample. 
 
BRCA1 testing intentions. We evaluated participants’ readiness for testing based on self-
reported intentions by using a measure adapted from a previous study [19]. The following 
information was presented orally: 'Scientists believe that, in some families, women who develop 
breast cancer have inherited a particular gene that makes them susceptible to cancer. It is possi-
ble to perform a blood test to determine which members of these families have this breast cancer 
gene. A woman who has the gene would have an extremely high risk of developing breast cancer 
in her lifetime. A woman who didn’t have the gene would have the same risk of developing 
breast cancer as a woman with no family history of breast cancer. Imagine that this test was 
made available to you, what would your plans regarding the test be?° Five response options 
ranged from planning to take the test within the next 30 days to not planning to take the test 
within the next 6 months. A dichotomous variable, intent to have a genetic test, was created by 
recoding the variable assessing readiness to have a genetic test as planning to have a genetic test 
within the next 30 to 60 days or distant future vs all other replies. 
 
Analysis 
Descriptive statistics (i.e., frequencies and means) were used to describe the study population in 
terms of demographic characteristics, clinical factors, psychosocial responses, and genetic testing 
items. Subsequently, contingency table analysis (X
2
 and Fisher’s exact tests) for categorical 
variables and t tests for continuous variables were computed to examine associations between 
intention to have BRCA1 testing and the sociodemographic, clinical, and psychological 
variables. Two- sided P values <0.05 were considered statistically significant. 
 
Logistic regression analysis with general estimating equations [21] was used to determine 
predictors of intention to have a genetic test while controlling for type of interview (i.e., in-
person vs telephone) and correlated responses within families. Any variable having univariate 
associations ofP <0.25 with intent tohave a genetic test was a candidate for entry into the logistic 
model. Backwards elimination procedures were used to determine which variables were retained 
in the final model [22]. Variables that had a P < 0.10 were also included, as was type of 
interview (i.e., in person vs telephone). 
 
RESULTS 
Response Rate and Analysis of Response Bias 
Of the 121 eligible K2099 members, 79% (n = 95) participated in the present study. Compared to 
nonparticipants, participants were more likely to be female (X
2
 = 9.2; df = 1; P < 0.01) and to 
have participated in the prior linkage study (X
2
 = 5.5; df = 1; P = 0.02). Respondents tended to be 
younger (x = 43 years; SD = 13.2) than nonrespondents (x = 50 years; SD = 15.5), although this 
difference was not statistically significant (t = 1.4; df = 106,P = 0.13). Geographic location 
(southeastern Louisiana vs other) (X
2
 = 4.4; df = 1; P = 0.76) was not related to participation. 
 
Background and Health Care-Related Factors 
Characteristics of the study population are shown in Table 1. Participants were on average 43 
years old (SD = 13.2; range = 18±78). The vast majority reported that they went to a specific 
HCP or clinic, where rapport 
 
 
and communication with health professionals were felt to be very high. 
 
Twenty-eight percent of women 25–39 years indicated that they had had a mammogram within 
the past year; the most common reason given for not doing so was that they were “too young.' 
Other reasons were: “a mammogram was never scheduled,' “nothing was found during self-
examination of the breasts,' “no lump was found,' and “fear.' Fifty-two percent of women ?40 
years reported having had a mammogram within the past year; reasons for not doing so included: 
“not suggested by doctor,' “concentrating on spouse' s illness,' “forgot to schedule one,' and 
“haven' t taken the time.' Eighty percent of women ≥25 years and 63% of women ≥40 years 
reported having a CBE within the past year. One hundred percent of women between the ages of 
18 and 24 reported performing BSE at least monthly, while 85% of women 25–39 years and 73% 
of women ≥40 years of age reported performing monthly BSE. 
 
Less than half (48%) of unaffected females, and 18% of males, reported that a care provider had 
discussed their own or their female relatives' breast cancer risk with them. Overall, two-thirds of 
the participants indicated that they wished to learn more about their familial risk. The most 
common informational needs were understanding why a family is cancer prone, causes of cancer, 
estimation of risk, and measures to reduce risk. 
 
Knowledge, Attitudes, and Psychological Variables 
As per Table 2, participants' knowledge about the genetics of breast and ovarian cancer was 
limited. The average knowledge score was 3.2 (SD = 2.1; range = 0–7) out of a total of 9. Thirty-
three percent of the items were answered correctly by the majority of participants. Only 5% 
knew that the population prevalence of hereditary breast and ovarian cancer gene mutations was 
not 1 in 9. Furthermore, 40% did not know that having an altered breast cancer gene increases 
the risk of breast and ovarian cancer, and 54% did not know that a hereditary breast and ovarian 
cancer gene mutation can be inherited from one' s biological father. 
 
The most commonly cited cause of breast cancer was heredity. Other perceived causes of breast 
cancer were lifestyle factors (e.g., diet, smoking, and lack of exercise), environmental factors 
(e.g., pollutants from chemical plants and inhalation of baking soda or “scrub'), viruses, 
psychological stress, “spiritual condition,' “not taking care of self,' and injury to the breast. 
 
When asked to rate their likelihood of being a breast cancer gene mutation carrier, 31% guessed 
that their chances were at least 50%, while 56% did not know. Similarly, 21% guessed that their 
chances of being an ovarian cancer gene mutation carrier were at least 50%, while 64% did not 
know. 
 
Data concerning perceived advantages, limitations, and risks of genetic testing are shown in 
Table 3. More than half of the participants endorsed all of the advantageous items and 38%ofthe 
limitation and risk items. 
 
Psychological distress was relatively high. Overall, the mean CES-D score was 15.0 (SD = 12.4); 
scores did not significantly differ by gender or cancer status (affected vs unaffected). Using the 
standard cutoff point for the CES-D scale (15/16), the prevalence of depressive symptoms was 
41%. The median score on the Intrusion subscale of the Impact of Event Scale was 9.0 (range 0–
35); scores did not significantly differ by gender or cancer status. Because the responses were not 
normally distributed, this measure was first divided into tertiles and then dichotomized as 
low/moderate distress (first and second tertiles; Intrusion subscale score = 0–12) and high 
distress (third tertile; Intrusion subscale score ≥13). 
 
Factors Associated with Intent to Have a Genetic Test 
If a BRCA1 test were made available, 82% of the participants indicated that they would seek 
genetic testing: 45% within the next 30 days, 35% within the next 6 months, and 2% in the more 
distant future. Fourteen percent indicated that they did not plan to take the test but could change 
their mind; 4% were unsure. 
 
Sociodemographic and clinical factors associated with intention to have BRCA1 testing are 
shown in Table 4. Younger age was associated with interest in genetic testing (P = 0.02), as were 
a prior history of breast or ovarian cancer (P = 0.05) and one or more first-degree relatives with 
breast and/or ovarian cancer (P = 0.05). There were no significant associations between those 
who intend to and those who do not intend to have a genetic test with regard to gender, income, 
religion, having health insurance, having a primary care provider, provider rapport, and provider 
communication. Type of interview was not significantly associated with intent to have a genetic 
test (P = 0.68). 
 
Table 5 presents cognitive and psychological variables associated with genetic testing intentions. 
Participants who believed that their chances of being a 
 
 
mutation carrier were ?t50% (35.9%) were more likely to indicate interest than those who 
believed their risk was <50% (7.7%). Likewise, testing intentions were higher among 
participants who perceived their risk of ovarian cancer to be 50% or greater than among those 
who believed their risk was lower, although this association was marginally significant. Higher 
levels of cancer- specific distress were observed among participants who intend to have a genetic 
test than among those who do not intend to be tested (P = 0.05). Participants with depressive 
symptoms were more likely to indicate interest in genetic testing; however, this difference was 
marginally significant (P < 0.10). Knowledge about familial breast cancer genetics and God 
Locus of Health Control score were not associated with genetic testing intentions. 
 
Multivariate Analysis 
The eight variables selected for logistic regression analysis with generalized estimating analysis 
included the following: age, education, prior history of breast and/or ovarian cancer, number of 
first-degree relatives with breast and/or ovarian cancer, perceived risk of being a carrier of an 
altered hereditary breast cancer gene, presence of depressive symptoms, knowledge about breast 
cancer genetics, and cancer-specific psychological distress. Perceived risk of being a hereditary 
ovarian gene mutation carrier was highly correlated with the variable assessing perceived risk of 
being a carrier of a breast cancer gene mutation (Pearson’s r = 0.80); therefore, this variable was 
not entered into the model. Having at least one first-degree relative with breast and/or ovarian 
cancer (OR = 5.1; 95% CI = 1.2– 20.9), perceiving that the risk of being a gene carrier was 
?t50% (OR = 64.3; 95% CI = 5.1–803.9), and not 
 
knowing their risk (OR = 10.9; 95% CI = 2.1–57.7) were independent predictors of intention to 
get genetic testing for breast cancer. Although the variables family identification number and 
interview type were not significant predictors, they were retained in the models as control 
variables. 
 
DISCUSSION 
This cross-sectional survey provided insight into the knowledge deficits, needs, and desires of an 
African-American family with a BRCA1 mutation. Despite limited knowledge, many 
participants had a high level of interest about cancer susceptibility testing. This finding supports 
prior studies of genetic testing interest in cancer predisposition testing among unaffected individ-
uals, including African Americans [5,23f26]. A limitation of our study is that we measured 
intention to undergo genetic testing rather than actual behavior. Prior research has shown that 
interest in BR CA1/2 testing overestimated actual uptake among Caucasians [18,27f29]. 
Research on uptake rates among high-risk African Americans is an area for evaluation. 
 
Few prior studies have assessed the influence of spirituality and religion on genetic testing 
decisions. A recent study by Schwartz et al. noted a positive association between spiritual faith 
and acceptance of genetic testing [30]. However, another recent study found no such association 
[27]. These study populations were predominantly Caucasian; data indicate that religiosity or 
spirituality may have a greater influence on health behaviors among African Americans [31]. We 
observed a negative association between beliefs about God as a controlling force over one’s 
health and adherence to breast cancer screening guidelines among members of K2099 [32]. 
Thus, assessment of the effects of specific spiritual and religious beliefs and their influence on 
health behaviors awaits further research. 
 
Insufficient communication with providers is not limited to members of high-risk families. A 
survey of breast cancer survivors found that only 8% had discussed genetic testing with HCPs 
[33]. Our observations revealed evidence of inadequate communication between the study 
subjects and their HCPs, despite generally favorable attitudes toward these providers. Few of the 
participants had discussed cancer causes and treatment, genetic testing, and personal or familial 
risk factors. Our observations highlight the need for a careful initial assessment of baseline 
knowledge, with the goal of enhancing understanding of specific information needs. Subsequent 
discussions could focus on individual beliefs and misconceptions, limitations of testing and con-
cerns related to minimizing these limitations, informed consent issues, implications of test 
results, and risk factors for cancer. Previous research has shown that women from different 
socioeconomic classes tend to vary in the type of information desired [34. Thus, education and 
counseling should be tailored to the attitudes, education level, and socioeconomic status of the 
individual patient. Likewise, prior studies have shown that patients often wish to know their 
HCP’s recommendations about whether or not genetic testing should be performed [35f36]; this 
attitude maybe especially prevalent in women from known high-risk families. When particularly 
vulnerable populations indicate that they want their HCPs to advise them about whether they 
should be tested, it does not necessarily follow that HCPs should give such advice. HCPs not 
equipped to provide genetic counseling should make referrals to qualified professionals who can 
provide specialized services. A recent study reported that even after genetic counseling and 
testing, utilization of breast cancer screening is suboptimal [37]. Moreover, adherence to 
screening recommendations in our study was poor. Given the high breast cancer mortality rates 
among African-American women [38], use of mammography among participants was 
disappointing; this finding is consistent with other studies [39]. A number of possible factors 
may be relevant; some relate to under referral by HCPs, while others may involve characteristics 
of participants. HCPs may lack knowledge about cancer genetics and screening guidelines for 
high-risk women and may not be taking detailed family histories to assess risk factors. In 
addition, physicians are less likely to recommend mammography for African-American women 
[39]. 
 
Some caution should be used when interpreting these findings. Our participants generally had 
favorable attitudes toward their HCPs in terms of communication and rapport. However, many 
African Americans have a distrust of the medical system; this may inhibit them from using 
medical services [40]. Thus, our findings may not reflect the beliefs, attitudes, and knowledge 
among other African Americans who carry a gene mutation associated with hereditary breast 
cancer. The odds ratios have wide confidence intervals and are imprecise, possibly due to the 
small sample size. The choice of in-person or telephone interviews may be suboptimal. However, 
this design was established in partnership with key informants of K2099 as a strategy to enhance 
recruitment. We did not observe statistically significant differences in responses between those 
who completed in-person versus telephone interviews. 
 
In conclusion, our study provides important information about knowledge deficits as well as 
attitudes and beliefs to consider when designing a genetic education and counseling intervention 
for this kindred and other similar high-risk families. Our participants clearly wished to expand 
their knowledge in hopes of making optimal decisions about cancer screening and genetic 
testing. If high-risk individuals are to benefit from such programs, assessment of baseline 
knowledge levels must continue. Services should be tailored to the attitudes, beliefs, and 
educational level of recipients, as well as care providers who are often perceived as trusted 
information sources. It is vital that the views of high-risk groups such as this kindred be 
considered in the development and implementation of programs and clinical protocols intended 
for them. Issues such as genetic susceptibility, privacy rights, and informed consent may well be 
viewed in different ways by the providers and the recipients of information. Further research on 
the psychosocial and behavioral outcomes of genetic counseling and cancer predisposition will 
help guide culturally sensitive interventions that promote adherence to appropriate cancer 
prevention and screening guidelines and minimize adverse psychological and social 
consequences. 
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